Two studies demonstrated that a carefully adjusted, prolonged low-dose IL-2 treatment led to the recovery of TFR/TFH immune balance and successfully mitigated pathogenic B cell responses, as well as kidney damage [50,51]. This evidence concerns the gene TFRC and Nephropathy.